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Clinical PerspectiveWhat Is New?Here, we study a kindred with several members showing a severe atrial cardiomyopathy phenotype and identify a myosin light‐chain 4 (*MYL4*) loss‐of‐function mutation as the probable cause.Rat models, created by knocking out the *MYL4* gene as well as by knocking in the human *MYL4 p.E11K* mutation, reproduce the clinical phenotype and point to enhanced apoptotic and profibrotic signaling as a central mechanism, providing new insights into the molecular basis of atrial cardiomyopathy.What Are the Clinical Implications?MYL4 is essential for atrial electrical, functional, and structural integrity, and MYL4 dysfunction can produce severe inherited atrial cardiomyopathy.

Introduction {#jah32642-sec-0008}
============

Whereas ventricular cardiomyopathy is a well‐established entity with clear diagnostic and therapeutic implications, atrial cardiomyopathy represents a relatively new concept in active development.[1](#jah32642-bib-0001){ref-type="ref"} A wide range of factors contributes to the development of atrial cardiomyopathy, most commonly in association with ventricular pathology.[1](#jah32642-bib-0001){ref-type="ref"} To date, few primary cardiomyopathies with highly atrial‐selective manifestations have been recognized, but these may be very instructive about the mechanisms underlying the broad range of atrial cardiomyopathies.[2](#jah32642-bib-0002){ref-type="ref"} Genetic analyses of atrial cardiomyopathy are, so far, limited.[2](#jah32642-bib-0002){ref-type="ref"} Mutations in the natriuretic peptide precursor A gene are associated with familial atrial cardiomyopathy; long‐term follow‐up of natriuretic peptide precursor A--mutant patients shows progressive fibrosis associated with atrial standstill, a severe clinical scenario characterized by complete loss of atrial excitability.[3](#jah32642-bib-0003){ref-type="ref"}

Myosin light‐chain 4 (*MYL4*) encodes an essential myosin light chain that is specifically expressed in human atria after birth.[4](#jah32642-bib-0004){ref-type="ref"} The essential light chain forms part of the actomyosin cross‐bridge, providing structural support for the α‐helical neck region of the myosin heavy chain and modulating actin‐activated ATPase activity.[5](#jah32642-bib-0005){ref-type="ref"} The ventricular analog, a protein encoded by *MYL3*, is downregulated in failing or hypertrophied hearts and partly replaced by re‐expression of *MYL4* in the context of the fetal‐pattern remodeling typical of ventricular pathology.[4](#jah32642-bib-0004){ref-type="ref"} Recently, Gudbjartsson et al reported that *MYL4* is linked to atrial cardiomyopathy,[6](#jah32642-bib-0006){ref-type="ref"}, [7](#jah32642-bib-0007){ref-type="ref"} with a frameshift mutation in *MYL4* associated with early‐onset familial atrial fibrillation (AF) and bradyarrhythmias requiring pacemaker insertion. Orr et al[8](#jah32642-bib-0008){ref-type="ref"} also reported that heterozygous *MYL4 p.Glu11Lys* mutation causes familial AF. They found that expression of the analogous mutation in zebrafish leads to atrial enlargement and electrical abnormalities, without AF per se. This work presents the only animal‐model data available regarding the pathophysiology associated with MYL4‐dysfunction, and is limited by the fact that the zebrafish has a primitive heart tube with only 1 atrial and ventricular chamber, with (unlike humans) equal atrial and ventricular expression of the orthologous gene.

We identified a Chinese family with atrial tachyarrhythmias, a high incidence of atrial standstill, and severe bradyarrhythmias. Based on exome sequencing of this family, we identified a rare missense variant of *MYL4* (*p.E11K*), which had perfect cosegregation with atrial standstill in a large multiplex pedigree. Because these studies suggested that the MYL4 was crucial for atrial functional integrity, we generated a series of rat models using CRISPR/Cas9‐mediated genome editing to define the function of MYL4, as well as to validate the ability of MYL4 dysfunction to cause the atrial abnormalities we found in patients and to define underlying mechanisms.

Methods {#jah32642-sec-0009}
=======

Additional methodological details are available in Data [S1](#jah32642-sup-0001){ref-type="supplementary-material"}.

Large Atrial Standstill Pedigree and Clinical Features {#jah32642-sec-0010}
------------------------------------------------------

We collected a large pedigree in which 6 family members were diagnosed as showing atrial standstill. The inheritance pattern was very likely to be autosomal dominant (Figure [1](#jah32642-fig-0001){ref-type="fig"}A). The proband and her family members provided written informed consent for the study according to a clinical research protocol approved by the Ethics Committee of Shanghai Tenth People\'s Hospital.

![Pedigree and clinical data of the atrial standstill family. A, Pedigree of the atrial standstill family, 44 family members were clinically evaluated and 6 were diagnosed as having atrial standstill. B, The ECG records of the 3 patients (I‐7, II‐1, and II‐3) with total atrial standstill: The proband (I‐7) had atrial flutter (indicated by arrows) with junctional escape rhythm and atrial fibrillation at different ages and finally developed atrial standstill and required pacemaker implantation. Another 2 patients (II‐1, II‐3) also required pacemaker implantation; no P waves were found after atrial pacing artifacts (indicated by arrows). C, II‐19, II‐21, and III‐10 were diagnosed as having partial atrial standstill. III‐10, aged 14, had a normal ECG and no symptoms of palpitations or syncope. Though P waves were found in the surface ECGs of these patients, the A wave was absent on TTE. Atrial flutter, atrial fibrillation (II‐19), and sinus arrest (pauses up to 2.3 seconds in II‐19) occurred when they aged. ECG indicates standard 12‐lead electrocardiography; TTE, transthoracic ultrasound.](JAH3-6-e007030-g001){#jah32642-fig-0001}

Standard 12‐lead ECG and transthoracic echocardiography (TTE) were used to analyze atrial electrical and mechanical activity, respectively. TTE parameters of the affected patients are shown in Table [S1](#jah32642-sup-0001){ref-type="supplementary-material"}. The diagnosis of atrial standstill was established according to the following criteria: absence of P wave on the surface 12‐lead ECG; inability to stimulate the atria on invasive electrophysiological study[9](#jah32642-bib-0009){ref-type="ref"}; and/or loss of the A wave on TTE. Examples of illustrative ECG and TTE data are shown in Figure [1](#jah32642-fig-0001){ref-type="fig"}B and [1](#jah32642-fig-0001){ref-type="fig"}C.

Exome Sequencing {#jah32642-sec-0011}
----------------

DNA were extracted from peripheral blood. After excluding mutations in *SCN5A* and *GJA5* known to cause atrial standstill by Sanger sequencing, we performed high‐throughput exome capture sequencing for 2 affected family members, II1 and II3, at the Beijing Genomics Institute in Shenzhen China (for details, see Data [S1](#jah32642-sup-0001){ref-type="supplementary-material"}).

Calling and Prioritizing Exome Sequence Variants {#jah32642-sec-0012}
------------------------------------------------

The paired‐end short reads from exome sequencing were mapped onto the UCSC human reference genome by BWA.[10](#jah32642-bib-0010){ref-type="ref"} The Genome analysis toolkit (GATK)[11](#jah32642-bib-0011){ref-type="ref"} was used to recalibrate the alignments and to call single‐nucleotide variants and short insertion‐deletions (Indels). We prioritized the sequence variants by multilayer resources and functions using KGGSeq (V0.8), (<http://grass.cgs.hku.hk/limx/kggseq/>).[12](#jah32642-bib-0012){ref-type="ref"} For details, see Data [S1](#jah32642-sup-0001){ref-type="supplementary-material"}.

Validation of Candidate Mutations and Genes {#jah32642-sec-0013}
-------------------------------------------

A short list of sequence variants prioritized by KGGSeq (V0.8) was validated for all available family members by Sanger sequencing. In addition, for validated sequence variants showing perfect cosegregation with disease, we examined the frequency of mutant alleles in 200 unrelated controls without history of heart disease by Sanger sequencing. In the genomic region perfectly cosegregating with disease, we genotyped 47 sequence variants (covering around 38 Mbp) in all family members by Sequenom MassARRAY system (Sequenom, San Diego, CA). SimWalk2 was used to calculate the logarithm of the odds scores of multipoint parametric linkage analysis.[13](#jah32642-bib-0013){ref-type="ref"} We then ranked all genes in the significant linkage region according to their pathogenic potential with 2 widely used bioinformatics tools, Endeavour[14](#jah32642-bib-0014){ref-type="ref"} and GeneWanderer.[15](#jah32642-bib-0015){ref-type="ref"} Based on this information and the literature, we identified an *MYL4* point mutation (31 G→A), causing a glutamic acid to lysine mutation at position 11, as the most likely causative candidate.

Generation of *MYL4 p.E11K* Rats, *MYL4 KO* Rats, and *MYL4 Deletion* Rat Models {#jah32642-sec-0014}
--------------------------------------------------------------------------------

All the animal procedures conformed to NIH guidelines (Guide for the Care and Use of Laboratory Animals) and were approved by the Animal Care and Use Committees of Shanghai Tenth People\'s Hospital.

MYL4 mutant rat strains were generated by CRISPR/Cas‐mediated genome editing. In brief, Cas9 mRNA and sgRNA targeting exon 1 of *MYL4* gene was in vitro synthesized as previously described.[16](#jah32642-bib-0016){ref-type="ref"}, [17](#jah32642-bib-0017){ref-type="ref"} One‐cell rat embryos were obtained by superovulation of females the next morning after mating. The zygotes were cultured in KSOM embryo culture medium (Millipore, Billerica, MA) before injection. TE solution containing 12.5 ng/μL of gRNA and ≈25 ng/μL of Cas9 mRNA was injected into the cytoplasm of 1‐cell embryos through the microinjection needle. Injections were performed using an Eppendorf transferMan NK2 micromanipulator. Injected embryos were transferred into pseudopregnant female rats immediately after injection. Tail genomic DNA of F0 rats was extracted and amplified for sequencing.

Surface ECG and TTE {#jah32642-sec-0015}
-------------------

Surface ECGs were recorded with a biological signal acquisition amplifier (BL‐420S; Taimeng Co, Chengdu, China). For TTE, transthoracic 2‐dimensional and M‐mode images were obtained with a Visualsonics high resolution VEVO 2100 system (VisualSonics, Toronto, Ontario, Canada) with a 20‐MHz transducer. For details, see Data [S1](#jah32642-sup-0001){ref-type="supplementary-material"}.

Immunohistochemistry {#jah32642-sec-0016}
--------------------

Serial 5‐mm‐thick atrial cryosections were stained with Masson trichrome, counterstained with hematoxylin, and quantified with Image‐Pro Plus 6.0 software (version 6.0; Media Cybernetics, Inc, Rockville, MD). Fibrosis was quantified and expressed as percent cross‐sectional area, excluding blood vessels and perivascular tissue. Terminal deoxynucleotidyl transferase dUTP nick end labeling staining (Roche 11684817910 kit; F. Hoffmann‐La Roche AG, Basel, Switzerland) was used as an index of apoptosis. Fluorescence images were obtained with a DMI6000 fluorescent microscope (Leica Microsystems Wetzlar GmbH, Wetzlar, Germany). The sources of the primary antibodies are listed in Table [S2](#jah32642-sup-0001){ref-type="supplementary-material"}.

Statistical Analysis {#jah32642-sec-0017}
--------------------

Continuous variables were described as mean±SEM. Normal distribution was verified with the Shapiro--Wilk test. If data were normally distributed, differences were analyzed by 1‐way ANOVA, following by post hoc analysis (*t* test with Bonferroni correction) to evaluate statistical significance. For data that were not normally distributed, a nonparametric multiple‐group comparison (Kruskal--Wallis) was performed, followed by a Wilcoxon test with Bonferroni post hoc correction to compare individual group means. All *P* values are 2‐sided. The null hypothesis was rejected at *P*\<0.05.

Results {#jah32642-sec-0018}
=======

Clinical Profile {#jah32642-sec-0019}
----------------

We collected an unusually large pedigree of a family with inherited atrial cardiomyopathy and atrial standstill as a prominent feature, affecting 6 individuals of 44 family members distributed into 2 branches, with a typical dominant inheritance pattern (Figure [1](#jah32642-fig-0001){ref-type="fig"}A). The proband (I‐7) initially visited our hospital for bradycardia (Figure [1](#jah32642-fig-0001){ref-type="fig"}B, left) and lower extremity edema. Atrial flutter with a slow ventricular response was followed approximately 4 years later by atrial standstill, neither right nor left atria could be captured during invasive electrophysiological (Figure [S1A](#jah32642-sup-0001){ref-type="supplementary-material"}). II‐1 and II‐3 also developed total atrial standstill (Figure [1](#jah32642-fig-0001){ref-type="fig"}B, right): Although they were implanted with dual chamber pacemakers, their atria could not be captured by atrial pacing. These patients had very similar clinical histories, all suffering from bradycardia at around 20 years old, followed by palpitations and reduced exercise tolerance between 30 and 40 years of age. After 40, all patients developed symptoms of heart failure.

II‐19, II‐21, and III‐10 showed partial atrial standstill (Figure [1](#jah32642-fig-0001){ref-type="fig"}C). II‐19 and II‐21 had a history of paroxysmal AF with junctional escape rhythm, along with low‐amplitude P waves and sinus‐node dysfunction (Figure [1](#jah32642-fig-0001){ref-type="fig"}C and Figure [S1](#jah32642-sup-0001){ref-type="supplementary-material"}). III‐10, aged 14, had a normal ECG and no symptoms of palpitation or syncope (Figure [1](#jah32642-fig-0001){ref-type="fig"}C), but markedly diminished atrial contractility on TTE. Despite the P wave in the surface ECG of these patients, the A wave was markedly reduced or absent on TTE.

No atrial or ventricular septal defects or valvular abnormalities were found in these patients. Details of ECG evolution as a function of age can be found in Figure [S1](#jah32642-sup-0001){ref-type="supplementary-material"}. Detailed ECG and TTE data are provided in Tables [S1](#jah32642-sup-0001){ref-type="supplementary-material"} and [S3](#jah32642-sup-0001){ref-type="supplementary-material"}, respectively.

Novel Candidate Genes Suggested by Exome Sequencing and Bioinformatic Analysis {#jah32642-sec-0020}
------------------------------------------------------------------------------

We then searched for candidate causal gene variants in this atrial cardiomyopathy pedigree. Because of failure to find any promising mutations in the 2 genes previously associated with atrial standstill, *SCN5A* and *GJA5*,[18](#jah32642-bib-0018){ref-type="ref"} we performed exome sequencing in 2 patients, II‐1 and II‐3. In total, 62 960 single‐nucleotide variants and 4192 insertions/deletions (Indels) were detected after stringent quality control using KGGSeq (V0.8),[12](#jah32642-bib-0012){ref-type="ref"} and we chose the top 60 single‐nucleotide variants (listed in Table [S4](#jah32642-sup-0001){ref-type="supplementary-material"}) for validation according to their predicted pathogenic probability.[19](#jah32642-bib-0019){ref-type="ref"} It turned out that 2 missense single‐nucleotide variants (c. 610G\>C of *TUBG2* and c. 31G\>A of *MYL4*) in 17q21 perfectly cosegregated with the dominant inheritance mode in the pedigree. To further map the specific linkage regions in 17q21, the multipoint parametric linkage analysis in 17q21 provided a maximal logarithm of the odds score of 5.3 (Figure [2](#jah32642-fig-0002){ref-type="fig"}A). Haplotype analysis showed a ≈6 Mbp (or ≈5 cM) region exclusively shared by patients.

![Genetic analysis. A, The multiple linkage analysis logarithm of the odds score in 17q21. B, Mutation (31G\>A) in *MYL4* confirmed by Sanger sequencing. C, The mutated locus is highly conserved across species. MYL4 indicates myosin light‐chain 4.](JAH3-6-e007030-g002){#jah32642-fig-0002}

Based on bioinformatic analysis, both GeneWanderer and Endeavour ranked *MYL4* in the top 2 genes in terms of its functional relationship to *SCN5A* and *GJA5* (listed in Tables [S5](#jah32642-sup-0001){ref-type="supplementary-material"} and [S6](#jah32642-sup-0001){ref-type="supplementary-material"}). Importantly, the identified missense mutation c. 31G\>A in *MYL4* changed the negatively charged residue (glutamic acid) to a positively charged 1 (lysine), *p.E11K*. This mutation was predicted to be pathogenic by KGGSeq (V0.8) under a combined prediction model[19](#jah32642-bib-0019){ref-type="ref"} of multiple deleteriousness and conservation scores (including SIFT,[20](#jah32642-bib-0020){ref-type="ref"} MutationAssessor,[21](#jah32642-bib-0021){ref-type="ref"} and GERP++[22](#jah32642-bib-0022){ref-type="ref"}). The *MYL4* mutation was confirmed in the entire pedigree by Sanger sequencing (Figure [2](#jah32642-fig-0002){ref-type="fig"}B). The mutation corresponded positionally to a negatively charged amino acid that is highly conserved across species (Figure [2](#jah32642-fig-0002){ref-type="fig"}C).

Of note, all 6 affected individuals carried the *MYL4* mutation, and none of 38 nonaffected family members that were sequenced showed the mutation. There were 3 additional family members (I‐1, I‐5, and the father of I‐7), who also had a history of bradycardia, but for whom neither DNA for sequencing nor sufficient clinical data to assess the precise phenotype were available.

*MYL4 p.E11K* Rats Show an Atrial Cardiomyopathy Phenotype {#jah32642-sec-0021}
----------------------------------------------------------

To assess the pathogenic contribution of the *MYL4 p.E11K* mutation, we constructed a knock‐in *MYL4 p.E11K* rat model with CRISPR/Cas‐mediated genome editing (Figure [3](#jah32642-fig-0003){ref-type="fig"}A and [3](#jah32642-fig-0003){ref-type="fig"}B). The P‐wave amplitude of *MYL4 E11K* ^*+/−*^ and *MYL4 E11K* ^*+/+*^ rats decreased progressively, accompanied by prolongation of the PR interval, from 15 days of age. The phenotype was more severe in homozygous rats, with 40% of *MYL4 E11K* ^*+/+*^ rats losing their P wave by 3 months of age and 80% at 6 months. Nevertheless, heterozygote (*MYL4 E11K* ^*+/−*^) rats also showed a clear phenotype, albeit less dramatic compared with homozygotes, with reduced P‐wave amplitude (Table [S7](#jah32642-sup-0001){ref-type="supplementary-material"}) and left atrial dilation (Table [S8](#jah32642-sup-0001){ref-type="supplementary-material"}) versus wild type (WT). The QRS duration was similar among all groups, indicating atrial‐specific electrical pathology (Figure [3](#jah32642-fig-0003){ref-type="fig"}C through [3](#jah32642-fig-0003){ref-type="fig"}E; Table [S7](#jah32642-sup-0001){ref-type="supplementary-material"}). No spontaneous atrial arrhythmias were observed in knock‐in rats during routine ECG recording.

![*MYL4 p.E11K* rat targeting strategies and atrial cardiomyopathic phenotype. A and B, The *MYL4 p.E11K* rat model was produced using CRISPR/Cas‐mediated genome editing. The genotypes were confirmed by Sanger sequencing. C, Representative ECGs from WT, heterozygous, and homozygous *MYL4 E11K* rats at different ages. D and E, Mean data for P‐wave amplitude and PR interval. P‐wave amplitude of *MYL4 E11K* ^*+/−*^ rats progressively decreased, with prolongation of the PR interval, from 15 days of age. WT Rats: N=9; *MYL4 E11K* ^*+/−*^ rats: N=15; *MYL4 E11K* ^*+/+*^ rats: N=10. F, Representative echocardiographic images from 3 rat genotypes. G and H, Mean data for left atrial dimension and left ventricular ejection fraction. The left atria progressively enlarged in both *MYL4 E11K* ^*+/−*^ and *MYL4 E11K* ^*+/+*^ rat hearts, starting at 3 months of age. For TTE, 4 to 5 rats/group were averaged. Data are mean±SEM. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001 vs WT, ^\#^ *P*\<0.05 among 15 days, 1 month, 3 months, and 6 months rats. ECG indicates standard 12‐lead electrocardiography; MYL4, myosin light‐chain 4; N, number; TTE, transthoracic ultrasound; WT, wild type.](JAH3-6-e007030-g003){#jah32642-fig-0003}

Echocardiography showed left atrial dilation (Figure [3](#jah32642-fig-0003){ref-type="fig"}F) in both *MYL4 E11K* ^*+/−*^ and *MYL4 E11K* ^*+/+*^ rats at 3 months and progressive increases with aging (Table [S8](#jah32642-sup-0001){ref-type="supplementary-material"}). For example, at 6 months, left atrial diameters were 4.5±0.3 mm in *MYL4 E11K* ^*+/+*^ and 3.8±0.1 mm in *MYL4 E11K* ^*+/−*^ rats, compared with 3.2±0.1 mm in WT (*P*\<0.001; Figure [3](#jah32642-fig-0003){ref-type="fig"}F through [3](#jah32642-fig-0003){ref-type="fig"}H; Table [S8](#jah32642-sup-0001){ref-type="supplementary-material"}).

In contrast to the clear atrial changes, right and left ventricular chamber sizes and ejection fraction were similar among the 3 genotypes, with no deviation greater than 20% and a small change of borderline statistical significance only at 3 months in *MYL4 E11K* ^*+/+*^ rats. There were no differences in growth parameters among the 3 genotypes in either male or female rats (Figure [S2](#jah32642-sup-0001){ref-type="supplementary-material"}).

Atrial Fibrosis and Cardiomyocyte Apoptosis in *MYL4 p.E11K* Rats {#jah32642-sec-0022}
-----------------------------------------------------------------

To further assess the atrial remodeling caused by *p.E11K* mutation, we collected atrial tissues from WT, *MYL4 E11K* ^*+/−*^ and *MYL4 E11K* ^*+/+*^ rats at ages of 2 days, 15 days, 1 month, 3 months, and 6 months. Left atrial fibrosis was quantified with Masson trichrome staining. *MYL4 E11K* ^*+/−*^ and *MYL4 E11K* ^*+/+*^ rats developed progressive left atrial fibrosis compared with WT rats, with statistically significant increases noted as early as 2 days of age (Figure [4](#jah32642-fig-0004){ref-type="fig"}A). At 2 days, 16.4±0.7% fibrous tissue content was observed in *MYL4 E11K* ^*+/+*^ rats and 8.4±1.5% in *MYL4 E11K* ^*+/−*^ rats, compared with 5.6±0.6% in WT (*P*\<0.001). At 6 months old, 27.6±5.8% fibrosis was observed in *MYL4 E11K* ^*+/+*^ rats and 12.0±1.0% in *MYL4 E11K* ^*+/−*^ rats versus 8.7±0.6% in WT (*P*=0.016; Figure [4](#jah32642-fig-0004){ref-type="fig"}A and [4](#jah32642-fig-0004){ref-type="fig"}B).

![*MYL4 p.E11K* causes atrial fibrosis and cardiomyocytes apoptosis. A and B, Atrial fibrosis obtained by Masson staining was averaged for 4 to 5 hearts per group (6--10 fields per heart for each group). C and D, Representative images and mean data for TUNEL staining of atrial sections (4--5 hearts per group, 6--10 fields per heart for each group) from WT,*MYL4 E11K* ^*+/−*^, and *MYL4 E11K* ^*+/+*^rats. E, Confocal immunofluorescence showed that TUNEL‐positive cells costained with α‐actin, indicating that they were cardiomyocytes. TUNEL‐positive staining is green. Nuclei are stained with DAPI (blue). Myocytes are stained for α‐actin (red). Arrows indicate TUNEL‐positive nuclei. Values are mean±SEM. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001 vs WT;, ^\#^ *P*\<0.05 among 15 days, 1 month, 3 months, and 6 months rats. DAPI indicates 4′,6‐diamidino‐2‐phenylindole; LA, left atrial; MYL4, myosin light‐chain 4; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; WT, wild type.](JAH3-6-e007030-g004){#jah32642-fig-0004}

Reparative fibrosis typically replaces cardiomyocytes that have been lost through apoptosis or necrosis.[23](#jah32642-bib-0023){ref-type="ref"}, [24](#jah32642-bib-0024){ref-type="ref"} The proportion of terminal deoxynucleotidyl transferase dUTP nick end labeling--positive nuclei was significantly increased in atrial tissue of heterozygous and homozygous *MYL4 p.E11K* rats compared with WT, even at 2 days of age (Figure [4](#jah32642-fig-0004){ref-type="fig"}C and [4](#jah32642-fig-0004){ref-type="fig"}D). Confocal immunofluorescence showed that terminal deoxynucleotidyl transferase dUTP nick end labeling--positive cells appeared to also costain with α‐actin (Figure [4](#jah32642-fig-0004){ref-type="fig"}E). We also performed proliferating cell nuclear antigen staining to obtain an index of fibroblast numbers. The percentage of proliferating cell nuclear antigen--positive nuclei increased significantly in atrial tissue for both *MYL4 E11K* ^*+/−*^ and *MYL4 E11K* ^*+/+*^ rats at day 15 (*P*\<0.001; Figure [S3A](#jah32642-sup-0001){ref-type="supplementary-material"} and [S3B](#jah32642-sup-0001){ref-type="supplementary-material"}).

There were no differences among WT, *MYL4 E11K* ^*+/−*^ rat and *MYL4 E11K* ^*+/+*^ rats in atrial or ventricular cardiomyocyte size, based on FITC‐conjugated wheat germ agglutinin staining (Figure [S4](#jah32642-sup-0001){ref-type="supplementary-material"}). Similarly, there were no differences in ventricular fibrous tissue content, apoptosis, or proliferating cell nuclear antigen--positive cell content among genotypes (Figures [S3C](#jah32642-sup-0001){ref-type="supplementary-material"}, [S3D](#jah32642-sup-0001){ref-type="supplementary-material"}, and [S5](#jah32642-sup-0001){ref-type="supplementary-material"}).

Activation of Profibrotic and Proapoptotic Signals in the *p.E11K* Cardiomyocytes In Vivo and In Vitro {#jah32642-sec-0023}
------------------------------------------------------------------------------------------------------

Atrial fibrosis can result from the activation of a variety of fibroproliferative signaling pathways.[25](#jah32642-bib-0025){ref-type="ref"}, [26](#jah32642-bib-0026){ref-type="ref"} Both small mothers against decapentaplegic and c‐Jun N‐terminal kinase phosphorylation was significantly increased in *MYL4 E11K* ^*+/+*^ (but not *MYL4 E11K* ^*+/−*^) atria (Figure [5](#jah32642-fig-0005){ref-type="fig"}A through [5](#jah32642-fig-0005){ref-type="fig"}C). Both *MYL4 E11K* ^*+/+*^ and *MYL4 E11K* ^*+/−*^ atria expressed significantly stronger expression of proapoptotic proteins B‐cell lymphoma 2--associated X protein and Caspase‐3 compared with WT (Figure [5](#jah32642-fig-0005){ref-type="fig"}D through [5](#jah32642-fig-0005){ref-type="fig"}G).

![Profibrotic and proaptotic signaling. A through C, Western blots and mean data for JNK and Smad signaling in atria from WT,*MYL4 E11K* ^*+/−*^, and *MYL4 E11K* ^*+/+*^rats. D through G, Western blots and mean data for Bax and Caspase‐3 expression in atria from WT,*MYL4 E11K* ^*+/−*^, and *MYL4 E11K* ^*+/+*^rats. Data are mean±SEM. Protein from 3 independent rat atrial samples were subjected to immunoblot for each groups. \**P*\<0.05. Bax indicates B‐cell lymphoma 2--associated X protein; Bcl‐2, B‐cell lymphoma 2; JNK, c‐Jun N‐terminal kinase; LA, left atrial; MYL4, myosin light‐chain 4; Smad, small mothers against decapentaplegic; WT, wild type.](JAH3-6-e007030-g005){#jah32642-fig-0005}

To independently assess the direct effects of the *MYL4* mutation on cardiomyocytes, we exposed cultured neonatal rat cardiomyocytes to WT MYL4 or MYL4^E11K^ overexpression by adenovirus‐mediated gene transfer in vitro (Figure [6](#jah32642-fig-0006){ref-type="fig"}A through [6](#jah32642-fig-0006){ref-type="fig"}C). Neonatal rat cardiomyocytes overexpressing MYL4^E11K^ showed increased apoptosis compared with WT (Figure [6](#jah32642-fig-0006){ref-type="fig"}D and [6](#jah32642-fig-0006){ref-type="fig"}E), along with upregulation of the proapoptotic protein, caspase‐3, and downregulation of the antiapoptotic protein, B‐cell lymphoma 2 (Figure [6](#jah32642-fig-0006){ref-type="fig"}F through [6](#jah32642-fig-0006){ref-type="fig"}I). In addition, MYL4^E11K^ overexpression also increased small mothers against decapentaplegic and c‐Jun N‐terminal kinase phosphorylation relative to MYL4‐WT (Figure [6](#jah32642-fig-0006){ref-type="fig"}F, [6](#jah32642-fig-0006){ref-type="fig"}J, and [6](#jah32642-fig-0006){ref-type="fig"}K). These data suggest that *MYL4 p.E11K* directly induces atrial profibrotic and proapoptotic signaling.

![Acute *MYL4 p.E11K* gene transfer causes NRCM apoptosis and activates profibrotic signaling. A through C, Western blot and quantitative RT‐PCR analysis of *MYL4* expression in NRCM exposed to gene transfer with different adenoviral constructs. D and E, Cardiomyocytes exposed to *MYL4 E11K* adenovirus showed significantly greater TUNEL‐positivity compared with WT. TUNEL‐positive staining is FITC (green). Nuclei are stained with DAPI (blue). Myocytes are stained for α‐actin (red). Arrows indicate TUNEL‐positive nuclei. F through K, Western blot analysis for proapoptotic protein caspase‐3 and antiapoptotic protein Bcl‐2 (F through I) and Smad/JNK signaling. Data are mean±SEM. The sample sizes were N=3 NRCM isolations per group with n=3 replicates from each isolate for each experiment. \**P*\<0.05. Bax indicates B‐cell lymphoma 2--associated X protein; Bcl‐2, B‐cell lymphoma 2; Ctr indicates control; DAPI, 4′,6‐diamidino‐2‐phenylindole; JNK, c‐Jun N‐terminal kinase; MYL4, myosin light‐chain 4; N, number; NRCM, neonatal rat cardiomyocytes; Smad, small mothers against decapentaplegic; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; WT, wild type.](JAH3-6-e007030-g006){#jah32642-fig-0006}

MYL4 protein expression decreased in *MYL4 p.E11K* knock‐in rats compared to WT rats (Figure [S6](#jah32642-sup-0001){ref-type="supplementary-material"}), and E11K protein overexpression in cultured neonatal rat cardiomyocytes reduced MYL4 protein levels (Figure [6](#jah32642-fig-0006){ref-type="fig"}A), suggesting that *MYL4 p.E11K* causes a loss of MYL4 protein stability and that this effect contributes to loss of function.

Atrial Arrhythmia and Heart Function in *MYL4 KO* Rats {#jah32642-sec-0024}
------------------------------------------------------

To further assess the functional contribution of *MYL4*, we constructed a *MYL4* knockout rat model (for gene editing strategy, see Figure [S6](#jah32642-sup-0001){ref-type="supplementary-material"}). *MYL4* knockout eliminated detectable MYL4 protein on western blot. Note that *MYL4 p.E11K* knock‐in similarly reduced MYL4 protein expression, pointing to loss of protein stability (Figure [S6](#jah32642-sup-0001){ref-type="supplementary-material"}). *MYL4 KO* rats demonstrated a similar phenotype to *MYL4 p.E11K* rats, but the phenotype manifested earlier and was more severe. Some homozygous *MYL4 KO* lost their P wave as early as 1 month of age. Overall, P‐wave amplitudes decreased significantly in homozygous *KO* rats at the age of 1 month, whereas the PR interval increased (see Figure [7](#jah32642-fig-0007){ref-type="fig"}A through [7](#jah32642-fig-0007){ref-type="fig"}C; Table [S9](#jah32642-sup-0001){ref-type="supplementary-material"}). On routine ECG recording, homozygous rats also showed spontaneous atrial arrhythmias, including atrial tachycardias, AF, and atrial standstill (Figure [7](#jah32642-fig-0007){ref-type="fig"}D; Table [S9](#jah32642-sup-0001){ref-type="supplementary-material"}). Heterozygous *KO* rats (*MYL4 HT*) also showed atrial electrical conduction disorders as they aged (Figure [7](#jah32642-fig-0007){ref-type="fig"}A through [7](#jah32642-fig-0007){ref-type="fig"}D; Table [S9](#jah32642-sup-0001){ref-type="supplementary-material"}). Echocardiography showed left atrial dilation in *KO* rats (8.7±2.2 mm in *KO* rats versus 5.4±0.1 mm in WT; *P*\<0.001; Figure [7](#jah32642-fig-0007){ref-type="fig"}E and [7](#jah32642-fig-0007){ref-type="fig"}F; Table [S10](#jah32642-sup-0001){ref-type="supplementary-material"}). *KO* rats also showed progressive atrial fibrosis (Figure [7](#jah32642-fig-0007){ref-type="fig"}H and [7](#jah32642-fig-0007){ref-type="fig"}I) and lost almost all contractile force generation (Figure [S7](#jah32642-sup-0001){ref-type="supplementary-material"}). In vitro, MYL4 knockdown in cultured myocytes led to a similar myocyte death phenotype to *MYL4 p.E11K* overexpression (Figure [S8](#jah32642-sup-0001){ref-type="supplementary-material"}), suggesting that loss of MYL4 function causes cell death that likely contributes to the progressive atrial cardiomyopathy phenotype.

![Atrial cardiomyopathy phenotype in *MYL4 KO* rats. A, Representative ECGs for WT, heterozygous, and homozygous *MYL4 KO* rats at different ages. B and C, Mean data for P‐wave amplitude and PR interval. WT Rats: N=9; *MYL4 HT* rats: N=12; *MYL4 KO* rats: N=5. D, Typical spontaneous atrial arrhythmias. E through G, Echocardiography showed left atrial enlargement in *KO* rats. WT Rats: N=3; *MYL4 HT* rats: N=5; *MYL4 KO* rats: N=3. H and I, *KO* rats developed atrial fibrosis (4--5 hearts per group, 6--10 fields per heart for each group). Data are mean±SEM. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001 vs WT; ^\#^ *P*\<0.05 among 1 month, 3 months, and ≥6 months rats. ECG indicates standard 12‐lead electrocardiography; HT, heterozygous; KO, knockout; MYL4, myosin light‐chain 4; N, number; WT, wild type.](JAH3-6-e007030-g007){#jah32642-fig-0007}

Though there was no difference in ventricular fibrosis among WT, *MYL4 HT*, and *MYL4 KO* rats (Figure [S9A](#jah32642-sup-0001){ref-type="supplementary-material"} and [S9B](#jah32642-sup-0001){ref-type="supplementary-material"}), moderate statistically significant decreases in left ventricular function were noted in 6‐month‐old *MYL4 KO* rats, which may have been attributed to atrial arrhythmia and/or atrial structural and contractile remodeling (Figure [7](#jah32642-fig-0007){ref-type="fig"}G; Table [S10](#jah32642-sup-0001){ref-type="supplementary-material"}).

Effects on Myosin ATPase Activity {#jah32642-sec-0025}
---------------------------------

In order to assess the molecular signature of MYL4 dysfunction, we constructed 3 types of recombinant plasmids: (1) pcDNA3.1‐*MYL4*‐GG (WT); (2) pcDNA3.1‐*MYL4*‐AA (the E11*K* mutation); and (3) pcDNA3.1‐*MYL4*‐12bp del (the *Del*, with 4 consecutive amino acids deleted near the *MYL4 p.E11* site), then expressed and purified the corresponding proteins in yeast. MYL4 modulates actin‐activated ATPase activity,[5](#jah32642-bib-0005){ref-type="ref"} and the ATPase activities of different proteins were analyzed based on the Km and Vmax of myosin. Both Km and Vmax were significantly smaller in the presence of MYL4‐E11K protein than MYL4‐WT protein (Figure [S10](#jah32642-sup-0001){ref-type="supplementary-material"}). MYL4‐Del protein did not affect myosin ATPase activity (Figure [S10](#jah32642-sup-0001){ref-type="supplementary-material"}). These results indicate that the MYL4‐E11K mutant protein specifically reduces the activity of myosin ATPase.

To relate effects on myosin ATPase activity to atrial remodeling and obtain an additional control for the specificity of the *MYL4 p.E11K* mutation, we constructed an additional rat model, with the same 4 consecutive amino‐acid deletion near the *MYL4 p.E11K* site (Figure [S6A](#jah32642-sup-0001){ref-type="supplementary-material"} and [S6C](#jah32642-sup-0001){ref-type="supplementary-material"}). Neither *MYL4* ^*del+/−*^ nor *MYL4* ^*del+/+*^ rats showed atrial or ventricular fibrosis, arrhythmia, or structural remodeling (Figure [8](#jah32642-fig-0008){ref-type="fig"} and Figure [S9C](#jah32642-sup-0001){ref-type="supplementary-material"} and [S9D](#jah32642-sup-0001){ref-type="supplementary-material"}; Tables [S11](#jah32642-sup-0001){ref-type="supplementary-material"} and [S12](#jah32642-sup-0001){ref-type="supplementary-material"}), indicating that mutations in the gene that do not affect myosin function do not cause atrial cardiomyopathy.

![*MYL4 del* mutation rats do not show atrial cardiomyopathy. A through C, ECG data for WT (N=4), heterozygous, and homozygous *MYL4 deletion mutation* rats at different ages. Neither the *MYL4* ^*del+/−*^ (N=5) nor *MYL4* ^*del+/+*^ (N=4) rats had significant arrhythmia. D through F, Echocardiography showed the absence of structural remodeling in *MYL4* ^*del+/−*^ and *MYL4* ^*del+/+*^ rats. WT Rats: N=3; *MYL4* ^*del+/−*^ rats: N=5; *MYL4* ^*del+/+*^ rats: N=3. G and H, Neither the *MYL4* ^*del+/−*^ nor *MYL4* ^*del+/+*^ rats had significant atrial fibrosis (4--5 hearts per group, 6--10 fields per heart for each group). ECG indicates standard 12‐lead electrocardiography; MYL4, myosin light‐chain 4; N, number; WT, wild type.](JAH3-6-e007030-g008){#jah32642-fig-0008}

Discussion {#jah32642-sec-0026}
==========

In this study, we first identified the missense mutation, c.31G\>A (*p.E11K*), as a candidate causal gene variant for atrial cardiomyopathy through genetic analysis of a large family with atrial standstill. We then confirmed the role of this mutation with the use of a series of novel rat models generated by CRISPR/Cas‐mediated genome editing. We found that normal MYL4 function is essential for atrial electrical, contractile, and structural integrity. MYL4 dysfunction, whether as a result of knockout or targeted knock‐in of the human mutation, causes early atrial fibrosis associated with enhanced proaptotoic and profibrotic signaling, associated with an atrial cardiomyopathy featuring atrial arrhythmia, atrial contractile failure, and atrial enlargement.

Relationship to Past Studies of *MYL4* Gene‐Variant--Associated Atrial Disease {#jah32642-sec-0027}
------------------------------------------------------------------------------

Orr et al recently described a family with early‐onset AF and an apparently causal *MYL4* mutation, p.Glu11Lys.[8](#jah32642-bib-0008){ref-type="ref"} Interestingly, this mutation results in the same E11K amino‐acid alteration that we observed in our kindred. This is a highly nonconservative mutation of an acidic to a basic amino acid, with the potential to strongly alter protein function. Affected individuals had early‐onset AF, evidence of atrial contractile dysfunction and conduction abnormalities requiring pacemaker insertion, a very similar clinical presentation to our patients. Gudbjartsson et al very recently identified a frameshift deletion in *MYL4* causing AF at an early age, pacemaker requirement, and a high incidence of stroke.[7](#jah32642-bib-0007){ref-type="ref"} The clinical features were predominantly atrial, but signs of mild ventricular dysfunction eventually developed, primarily in the fifties and sixties. The clinical features of affected patients in the reports by Orr et al and Gudbardtsson et al were similar overall to those of our patients. As in our patients, inheritance appeared to be dominant in the Orr kindred,[8](#jah32642-bib-0008){ref-type="ref"} whereas it was recessive in the Gudbjartsson study.[7](#jah32642-bib-0007){ref-type="ref"}

The only previous animal‐model data relating to these *MYL4* gene variants come from the Orr study,[8](#jah32642-bib-0008){ref-type="ref"} in which the investigators reproduced the orthologous mutation (E17K in *cMLC‐1*) in zebrafish. They noted abnormal sinoatrial impulse generation and bradycardia, along with prolonged P‐wave duration and atrial enlargement. They noted marked disruption of sarcomere structure as early as 5 days postfertilization with loss of Z‐discs.

Here, we created novel rat models of MYL4 dysfunction with the use of CRISPR/Cas gene editing. The affected rats confirmed the ability of MYL4 dysfunction, whether by knockout or by knock‐in of a gene variant reproducing the clinical E11K mutation, to produce the cardinal clinical features of atrial electrical dysfunction, loss of atrial contractility, and atrial dilation constituting a highly atrial‐selective cardiomyopathy. Proapoptotic and profibrotic signaling were enhanced in knock‐in rats, and this appeared to be a direct result of the mutation rather than secondary to the atrial cardiomyopathy phenotype, because in vitro gene transfer of the mutation into neonatal rat cardiomyocytes reproduced the signaling changes. Interestingly, evidence of apoptosis and atrial fibrosis was present in vivo as early as 2 days of age (Figure [4](#jah32642-fig-0004){ref-type="fig"}), well before substantial loss of P‐wave amplitude or increase in left atrial dimension (Figure [3](#jah32642-fig-0003){ref-type="fig"}). These observations are consistent with the notion that Z‐disc disruption affects the many macromolecular complexes involved in intracellular signaling that are located at the Z‐disc,[8](#jah32642-bib-0008){ref-type="ref"}, [27](#jah32642-bib-0027){ref-type="ref"} producing profound atrial cardiomyocyte remodeling. Unlike the zebrafish, in which the orthologous gene is expressed in both the atria and ventricles, in rats and humans MYL4 shows strong atrial‐selective expression, consistent with the atrial‐selective phenotype noted.

Both in clinical reports[7](#jah32642-bib-0007){ref-type="ref"} and in our rats, some evidence of ventricular dysfunction appeared later in life. Ventricular dysfunction may be a secondary consequence of atrial arrhythmias, bradycardia, and dyssynchronous contraction caused by the primary atrial cardiomyopathy, or may be attributed to ventricular consequences of the mutation related to a return of ventricular MYL4 expression because of cardiac dysfunction.[4](#jah32642-bib-0004){ref-type="ref"}

Insights Into Atrial Cardiomyopathy {#jah32642-sec-0028}
-----------------------------------

The term "atrial cardiomyopathy" first appeared in the literature in 1972.[28](#jah32642-bib-0028){ref-type="ref"} Kottkamp has argued that many cases of AF may be attributed to an underlying "atrial fibrotic cardiomyopathy".[2](#jah32642-bib-0002){ref-type="ref"}, [29](#jah32642-bib-0029){ref-type="ref"} Recently, a consensus has emerged, defining and characterizing the concept of atrial cardiomyopathy.[1](#jah32642-bib-0001){ref-type="ref"} Insights from genetic paradigms greatly contributed to our understanding of ventricular cardiomyopathies,[30](#jah32642-bib-0030){ref-type="ref"} but very little information has been available to date about genetic causes of atrial cardiomyopathy. Our identification of a pathological *MYL4* mutation causing atrial cardiomyopathy and the development of powerful new animal models with which to study its pathophysiology is a step forward in the understanding of atrial cardiomyopathy. Atrial fibrosis appears to be a very early development in the evolution of this model. Along with the direct activation of proapoptotic and profibrotic signaling by gene transfer of the pathogenic mutation in vitro, these results point to this entity as a prototype for fibrotic atrial cardiomyopathy and provide insights into the underlying mechanisms. Prominent pathological features include highly atrial‐selective cardiomyocyte apoptosis and tissue fibrosis (eg, see Figure [4](#jah32642-fig-0004){ref-type="fig"}). According to the EHRA/HRS/APHRS/SOLAECE expert consensus, our rat model would be classified as a type III atrial cardiomyopathy, which combines cardiomyocyte pathology and fibrosis.[1](#jah32642-bib-0001){ref-type="ref"}

Clinical Relevance {#jah32642-sec-0029}
------------------

Clinically, atrial cardiomyopathy caused by *MYL4* mutation progressed gradually in our patients: Despite sinus rhythm at a young age, contractile abnormalities were already evident, followed by atrial arrhythmia, atrioventricular block, and finally total atrial standstill. In the early stage of the condition, the ECG may appear normal and patients may have negligible symptoms. Nevertheless, TTE indicates reduced mechanical activity in the atria, implying that TTE may be a useful technique for the early identification of affected individuals in a disease‐bearing kindred.

Besides the specific rare familial entity we studied, our work can provide broader insights into the development of atrial cardiomyopathy. Signaling events of the type we identified have also been noted in various acquired forms of atrial cardiomyopathy.[31](#jah32642-bib-0031){ref-type="ref"} Further study in our rat models might allow for the identification of vulnerable molecular targets in atrial cardiomyopathy development that could produce new therapeutic approaches.

Potential Limitations {#jah32642-sec-0030}
---------------------

The phenotype of *MYL4* mutated or *KO* rats directly paralleled the ECG changes and atrial dysfunction that we observed in our patients. *MYL4 p.E11K* rats had evidence of apoptosis and atrial fibrosis at an early stage. Although the phenotype of *KO* rats was similar overall to that of the *MYL4 p.E11K* rats, it was generally more severe and developed faster. Atrial tachyarrhythmias were easily noted in *KO* rats, but were not apparent in the *MYL4 p.E11K* knock‐in animals. The greater susceptibility of *KO* rats may be attributed to their complete loss of MYL4 function. The absence of atrial tachyarrhythmias in knock‐in rats may be attributed to the fact that the only rhythm recordings available to us were standard ECGs; continuous telemetry might have revealed spontaneous arrhythmias. Although the phenotype of the knock‐in rats was similar to that of our patients, there were some differences, most notably in the occurrence of spontaneous arrhythmias. Some of the discrepancy may be attributed to the absence of extended rhythm recording in the rats. Alternatively, background genetic control may play a role in conditioning the phenotype and promoting atrial arrhythmogenesis in humans. Nevertheless, *KO* rats did manifest spontaneous atrial tachyarrhythmias, confirming the principle that MYL4 dysfunction is, by itself, sufficient to cause atria arrhythmogenesis.

The underlying molecular mechanism of the myosin ATPase activity reduction is complex. Force production is considered to be associated with the Pi release step and the transition from weakly (non‐force‐generating) to strongly attached (force‐generating) states.[32](#jah32642-bib-0032){ref-type="ref"} Both Km and Vmax of myosin head ATPase are lower in the MYL4‐E11K protein than MYL4‐WT protein.

The work provided in this article presents a novel model with which to study the MYL4‐mutation--related atrial cardiomyopathy and characterizes the model in relationship to the clinical presentation. However, the precise mechanisms underlying key processes like apoptotic cell death and atrial fibrosis in this model remain to be determined in future studies.

Conclusions {#jah32642-sec-0031}
===========

We have shown, with the use of novel genetically defined rat models, that MYL4 is essential for atrial electrical, functional, and structural integrity, and that MYL4 dysfunction can account for severe inherited atrial cardiomyopathy in an extended kindred. We have obtained evidence that atrial apoptotic cell death and fibrosis are very early findings and are apparent before any functional manifestations of atrial cardiomyopathy. These observations are consistent with an important pathophysiological role for enhanced proapoptotic and profibrotic signaling that is activated rapidly in the presence of the causative mutation. These biological findings have the potential to advance our understanding of the molecular basis of atrial cardiomyopathy and eventually to lead to new diagnosis and therapeutic modalities.
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